6-溴-2-乙氧基喹啉 | 1363386-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-溴-2-乙氧基喹啉
• 英文名称: 6-bromo-2-ethoxyquinoline
• CAS: 1363386-54-2
• 化学式: C₁₁H₁₀BrNO
• 分子量: 252.11
• InChiKey: ITFJNURSKVIXSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  6-溴-2-乙氧基喹啉 在 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 水 、 potassium acetate 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 tert-butyl 4-((4-amino-3-(2-ethoxyquinolin-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Development of Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitors with Potent Anti-Toxoplasma Activity

  摘要：

  Toxoplasmosis is a disease of prominent health concern that is caused by the protozoan parasite Toxoplasma gondii. Proliferation of T. gondii is dependent on its ability to invade host cells, which is mediated in part by calcium-dependent protein kinase 1 (CDPK1). We have developed ATP competitive inhibitors of TgCDPK1 that block invasion of parasites into host cells, preventing their proliferation. The presence of a unique glycine gatekeeper residue in TgCDPK1 permits selective inhibition of the parasite enzyme over human kinases. These potent TgCDPK1 inhibitors do not inhibit the growth of human cell lines and represent promising candidates as toxoplasmosis therapeutics.

  DOI：

  10.1021/jm201713h
• 作为产物：
  描述：

  6-溴-2-氯喹啉 、 乙醇 在 sodium ethanolate 、 sodium hydride 作用下， 以 1,4-二氧六环 为溶剂， 反应 4.0h， 以88%的产率得到6-溴-2-乙氧基喹啉
  参考文献：
  名称：

  基于吡唑并[3,4-d]嘧啶的蛋白激酶D抑制剂的设计，合成和生物学评估。

  摘要：

  蛋白激酶D（PKD）在各种癌症特征中的多重作用已被反复报道。因此，寻找新型PKD抑制剂及其作为抗肿瘤药的评价已引起了广泛的关注。在这项工作中，合成了新颖的基于吡唑并[3,4- d ]嘧啶的泛PKD抑制剂，其在位置1具有结构多样性，并对其生物学活性进行了评估。从3-IN-PP1（一种已知的PKD抑制剂，IC 50值在94-108 nM范围内）出发，发现化合物17m对PKD具有改善的生化抑制活性（IC 50 = 17-35 nM）。随后的细胞分析表明3-IN-PP1和17m抑制PKD依赖的cortactin磷酸化。此外，3-IN-PP1对PANC-1细胞显示出有效的抗增殖活性。最后，针对不同癌细胞系的筛选表明3-IN-PP1是一种有效且用途广泛的抗肿瘤药。

  DOI：

  10.1016/j.ejmech.2020.112638

文献信息

• Selectfluor-mediated regioselective nucleophilic functionalization of N-heterocycles under metal- and base-free conditions
  作者：Long-Yong Xie、Jie Qu、Sha Peng、Kai-Jian Liu、Zheng Wang、Man-Hua Ding、Yi Wang、Zhong Cao、Wei-Min He

  DOI：10.1039/c7gc03106h

  日期：——

  A facile, practical and environmentally attractive protocol for the direct diversification of N-heterocycles under ambient, metal- and base-free conditions was developed.

  在常温、无金属和无碱条件下，开发了一种简便、实用且环境友好的直接多样化N-杂环的协议。

• Development of 5-Aminopyrazole-4-carboxamide-based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy
  作者：Wenlin Huang、Matthew A. Hulverson、Ryan Choi、Samuel L. M. Arnold、Zhongsheng Zhang、Molly C. McCloskey、Grant R. Whitman、Robert C. Hackman、Kasey L. Rivas、Lynn K. Barrett、Kayode K. Ojo、Wesley C. Van Voorhis、Erkang Fan

  DOI：10.1021/acs.jmedchem.9b00069

  日期：2019.3.28

  Cryptosporidium is a leading cause of pediatric diarrhea worldwide. Currently, there is neither a vaccine nor a consistently effective drug available for this disease. Selective 5-aminopyrazole-4-carboxamide-based bumped-kinase inhibitors (BKIs) are effective in both in vitro and in vivo models of Cryptosporidium parvum. Potential cardiotoxicity in some BKIs led to the continued exploration of the 5-aminopyrazole-4-carboxamide scaffold to find safe and effective drug candidates for Cryptosporidium. A series of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (mouse infection model) assays and safety issues. Compound 6 (BKI 1708) was found to be efficacious at 8 mg/kg dosed once daily (QD) for 5 days with no observable signs of toxicity up to 200 mg/kg dosed QD for 7 days. Compound 15 (BKI 1770) was found to be efficacious at 30 mg/kg dosed twice daily (BID) for 5 days with no observable signs of toxicity up to 300 mg/kg dosed QD for 7 days. Compounds 6 and 15 are promising preclinical leads for cryptosporidiosis therapy with acceptable safety parameters and efficacy in the mouse model of cryptosporidiosis.